Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...
Tumors are good at adapting. They lose the markers that targeted therapies are built to find, evolve resistance to drugs designed to kill them, and build a hostile environment that neutralizes immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results